Aliskiren (Rasilez®) for the treatment of essential hypertension
All Wales Medicines Strategy Group (AWMSG)
Record ID 32012000412
English
Authors' recommendations:
Aliskiren (Rasilez®) is not recommended for use within NHS Wales for the treatment of essential hypertension. The clinical and cost effectiveness data presented was insufficient for AWMSG to recommend its use.
Details
Project Status:
Completed
Year Published:
2009
URL for published report:
http://www.wales.nhs.uk/sites3/docmetadata.cfm?orgid=371&id=124169&pid=24773
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Antihypertensive Agents
- Hypertension
- Amides
- Fumarates
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.